Piper Jaffray Cuts Price Target as Insys Therapeutics' (INSY) Guides to a Decline in Subsys Sales
Tweet Send to a Friend
Piper Jaffray maintained an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and cut the price target to $46.00 (from $49.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
